Modulation of nitric oxide pathway by multiligands/rage axis: A crossing point on the road to microvascular complication in diabetes

Current Enzyme Inhibition

Volumn 6, Issue 1, 2010, Pages 34-45

  Rojas, Armando ^a   Gonzalez, Deyarina ^b   Figueroa, Hector ^a   Morales, Miguel A ^c   Romero, Jacqueline ^a  

^a UNIVERSIDAD CATÓLICA DEL MAULE   (Chile)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF CHILE   (Chile)

Author keywords

Advanced glycation; Diabetic complications; Hyperglycemia; Inflammation; Ligands; Nitric oxide synthases; RAGE; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; CALGRANULIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH MOBILITY GROUP B1 PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN S 100;

AMINO ACID SUBSTITUTION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME MODIFICATION; ENZYME REGULATION; ENZYME STRUCTURE; GENE EXPRESSION; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 77951056536     PISSN: 15734080     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340810790712050     Document Type: Review

References (157)

1. Moncada, S.; Palmer, R.M.; Higgs, E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 1991, 43, 109-142.
2. Aronson, D. Hyperglycemia and the pathobiology of diabetic complications. Adv. Cardiol., 2008, 45, 1-16.
3. Lowe, P.N.; Smith, D.; Stammers, D.K.; Riveros-Moreno, V.; Moncada, S.; Charles, I.; Boyhan, A. Identification of the domains of neuronal nitric oxide synthase by limited proteolysis. Biochem. J., 1996, 314, 55-62.
4. Lowenstein, C.J.; Glatt, C.; Bredt, D.; Snyder, S.H. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc. Natl. Acad. Sci., 1992, 89, 6711-6715.
5. Nathan, C.; Xie, Q.W. Nitric oxide synthases: Roles, tolls, and controls. Cell, 1994, 78, 915-918.
6. Knowles, R. G.; Moncada, S. Nitric oxide synthases in mammals. Biochem J., 1994, 298, 249-258.
7. Marletta, M. A. Nitric oxide synthase: Aspects concerning structure and catalysis. Cell, 1994, 78, 927-930.
8. Shaul, P. W. Regulation of endothelial nitric oxide synthase: Location, Location, Location. Ann. Rev. Physiol., 2002, 64, 749-774.
9. Ponting, C.P.; Phillips, C.; Davies, K.E.; Blake, D.J. PDZ domains: targeting signalling molecules to sub-membranous sites. Bioassays, 1997, 19, 469-479.
10. Gonzalez, E.; Kou, R.; Lin, A.J.; Golan, D.E.; Michel, T. Subcellular targeting and agonist-induced site-specific phosphorylation of eNOS. J. Biol. Chem., 2002, 277, 39554-39560.
11. Alderton, W.K., Cooper, C.E.; Knowles, R.G. Nitric oxide synthases: structure, function and inhibition. Biochem. J., 2001,357, 593-615.
12. Crane, B.R.; Arvai, A.S.; Ghosh, D.K.; Wu, C.; Getzoff, E.D.; Stuehr, D.J.; Tainer, J.A. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science, 1998, 279, 2121-2126.
13. Cubberley, R.R.; Alderton, W.K.; Boyhan, A.; Charles, I.G.; Lowe, P.N.; Old, R.W. Cysteine-200 of human inducible nitric oxide synthase is essential for dimerization of haem domains and for binding of haem, nitroarginine and tetrahydrobiopterin. Biochem. J., 1997, 323, 141-146.
14. Matsuda, H.; Iyanagi, T. Calmodulin activates intramolecular electron transfer between the two flavins of neuronal nitric oxide synthase flavin domain. Biochim. Biophys. Acta, 1999, 1473, 345-355.
15. Chen, P.F.; Wu, K.K. Characterization of the roles of the 594-645 region in human endothelial nitric-oxide synthase in regulating calmodulin binding and electron transfer. J. Biol. Chem., 2000, 275, 13155-13163.
16. Salerno, J.C.; Harris, D.E.; Irizarry, K.; Patel, B.; Morales, A.J.; Smith, S.M.E.; Martasek, P.; Roman, L.J.; Masters, B.S.S.; Jones, C.L.; Weismann, B.A.; Lane, P.; Liu, Q.; Gross, S.S. An autoinhibitory control element defines calcium-regulated isoforms of Nitric Oxide Synthase. J. Biol. Chem., 1997, 272, 29769-29777.
17. Nishida, C.R.; De Montellano, P.R.O. Autoinhibition of endothelial nitric-oxide synthase. Identification of an electron transfer control element. J. Biol. Chem., 1999, 274, 14692-14698.
18. 2+/calmodulin-dependent electron transfer. J. Biol. Chem., 1999, 274, 30589-30595.
19. Dudzinki, D.M.; Igarasshi, J.; Greif, D.; Michel, T. The regulation and pharmacology of endothelial nitric oxide synthase. Ann. Rev. Pharmacol . Toxicol., 2006, 46, 235-276.
20. Lane, P.; Gross, S.S. Disabling a c-terminal autoinhibitory control element in endothelial nitric-oxide synthase by phosphorylation provides a molecular explanation for activation of vascular no synthesis by diverse physiological stimuli. J. Biol. Chem., 2002, 277, 19087-19094.
21. Siddhanta, U.; Presta A.; Fan, B.; Wolan, D.; Roussseau, D.L.; Stuehr, D.J. Domain swapping in inducible nitric-oxide synthase. electron transfer occurs between flavin and heme groups located on adjacent subunits in the dimer. J. Biol. Chem., 1998, 273, 18950-18958.
22. Li, H.; Raman, C.S.; Glaser, C.B.; Blasko, E.; Young, T.A.; Parkinson, J.F.; Whitlow, M.; Poulos, T.L. crystal structures of zincfree and -bound heme domain of human inducible nitric-oxide synthase. Implications for dimer stability and comparison with endothelial nitric-oxide synthase. J. Biol. Chem., 1999, 274, 21276-21284.
23. Xia, Y.; Roman, L.J.; Masters, B.S.S.; Zweier, J.L. Inducible nitricoxide synthase generates superoxide from the reductase domain. J. Biol. Chem., 1998, 273, 22635-22639.
24. 2+/calmodulindependent and tetrahydrobiopterin regulatory process. J. Biol. Chem., 1998, 273, 25804-25808.
25. Xia, Y.; Zweier, J.L. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc. Natl. Acad. Sci., 1997, 94, 6954-6958. (Pubitemid 27281972)
26. Kuzkayana, N.; Weissmann, N.; Harrison, D.G.; Dikalov, S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J. Biol. Chem., 2003, 278, 22546-22554.
27. Rojas, A.; Figueroa, H.; Morales, M.A.; Re, L. Facing up the ROS labyrinth - where to go? Curr. Vasc. Pharmacol., 2006, 4, 277-289.
28. Chartrain, N.A.; Geller, D.A.; Koty, P.P.; Sitrin, N.F.; Nussler, A.K.; Hoffman, E.P.; Billiart, T.R.; Hutchinson, N.I.; Mudgett, J.S. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. J. Biol. Chem., 1994, 269, 6765-6772.
29. Panaro, M.A.; Brandonisio, O.; Acquafredda, A.; Sisto, M.; Mitolovo, V. evidences for inos expression and nitric oxide production in the human macrophages. Curr. Drug Targets - Immune, Endocr. Metab. Disord., 2003, 3, 210-221.
30. Saura, M.; Zaragoza, C.; Bao, C.; McMillan, A.; Lowestein, C.J. Interaction of interferon regulatory factor-1 and nuclear factor [kappa]B during activation of inducible nitric oxide synthase transcription. J. Mol. Biol., 1999, 289, 459-471.
31. Gupta, A.K.; Kone, B.C. USF-1 and USF-2 trans-repress IL-1beta - induced iNOS transcription in mesangial cells. Am. J. Physiol. Cell Physiol., 2002, 283, C1065-1072.
32. Kolyada, A.; Madias, N. Transcriptional regulation of the human iNOS gene by IL-1beta in endothelial cells. Mol. Med., 2001, 7, 329-343.
33. Taylor, B.S.; De Vera, M.E.; Ganster, R.W.; Wang, Q.; Shapiro, R.A.; Morris, S.M. Jr.; Billiart, T.R.; Geller, D.A. Multiple NFkappa B enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J. Biol. Chem., 1998, 273, 15148-15156.
34. Marks-Konczalik J.; Chu, S.C.; Moss, J. Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappa bbinding sites. J. Biol. Chem., 1998, 273, 22201-22208.
35. Feng, X.; Guo, Z.; Nourbakhsh, M.; Hauser, H.; Ganster, R.; Shao, L.; Geller, D.A. Identification of a negative response element in the human inducible nitric-oxide synthase (hiNOS) promoter: The role of NFkB-repressing factor (NRF) in basal repression of the hiNOS gene. Proc. Natl. Acad. Sci., 2002, 99, 14212-14217.
36. Ganster, R.W.; Taylor, B.S.; Shao, L.; Geller, D.A. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc. Natl. Acad. Sci., 2001, 98, 8638-8643.
37. Xu, W.; Comhair, S.A.A.; Zheng, S.; Chu, S.C.; Marks-Konczalik, J.; Moss, J.; Haque, S.J.; Erzurum, S.C. STAT-1 and c-Fos interaction in nitric oxide synthase-2 gene activation. Am. J. Physiol. Lung Cell Mol. Physiol., 2003, 285, L137-148.
38. Vodovotz, Y. Control of nitric oxide production by transforming growth factor-[beta]1: mechanistic insights and potential relevance to human disease. Nitric Oxide, 1997, 1, 3-17.
39. Korhonen, R.; Lahti, A.; Hamalainen, M.; Kankaanranta, H.; Moilanen, E. Dexamethasone inhibits inducible nitric-oxide synthase expression and nitric oxide production by destabilizing mrna in lipopolysaccharide-treated macrophages. Mol. Pharmacol., 2002, 62, 698-704.
40. Lanone, S.; Manivet, P.; Callebert, J.; Launay, J.M.; Payen, D.; Aubier, M.; Boczkowski, J.; Mebazaa, A. Inducible nitric oxide synthase (NOS2) expressed in septic patients is nitrated on selected tyrosine residues: implications for enzymic activity. Biochem. J., 2002, 366, 399-404.
41. Pan, J.; Burgher, K.L.; Szcepanik, A.M.; Ringheim, G.E. Tyrosine phosphorylation of inducible nitric oxide synthase: implications for potential post-translational regulation. Biochem. J., 1996,314, 889-894.
42. Mitani, T.; Terashima, M.; Yoshimura, H.; Narai, Y.; Tanigawa, Y. TGF-[beta]1 enhances degradation of IFN-[gamma]-induced iNOS protein via proteasomes in RAW 264.7 cells. Nitric Oxide, 2005, 13, 78-87.
43. Marsden, P.A.; Heng, H.H.; Scherer, S.W.; Stewart, R.J.; Hall, A.V.; Shi, X.M.; Tsui, L.C.; Schappert, K.T. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J. Biol. Chem., 1993, 268, 17478-17488.
44. Gregg, A.R.; Lee, C.G.; Herman, G.E.; O'brien, W.E. Endothelial nitric oxide synthase (Nos3) maps to the proximal region of mouse chromosome 5. Mamm. Genome, 1995, 6, 152.
45. Lamas, S.; Marsden, P. A.; Li, G. K.; Tempst, P.; Michel, T. endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc. Natl. Acad. Sci., 1992, 89, 6348-6352.
46. Sessa, W.C.; Harrinson, J.K.; Barber, C.M.; Zeng, D.; Durieux, M.E.; D'angelo, D.D.; Lynch, K.R.; Peach, M.J. Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase. J. Biol. Chem., 1992, 267, 15274-15276.
47. Dudzinski, D.M.; Igarashi, J.; Greif, D.; Michel, T. The regulation and pharmacology of endothelial nitric oxide synthase. Ann. Rev. Pharmacol. Toxicol., 2006, 46, 235-276.
48. Connelly, L.; Jacobs, A.T.; Palacios-Callender, M.; Moncada, S.; Hobbs, A.J. Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J. Biol. Chem., 2003, 278, 26480-26487.
49. Gnanapandithen, K.; Chen, Z.; Kau, C.L.; Gorczynski, R.M.; Marsden, P. A. Cloning and characterization of murine endothelial constitutive nitric oxide synthase. Biochim. Biophys. Acta, 1996, 1308, 103-106.
50. Teichert, A.M.; Karantzoulis-Fegaras, F.; Wang, Y.; Mawji, I.A.; Bei, X.; Gnanapandithen, K.; Chen Z.; Kau C.L.; Gorczynski R.M.; Marsden, P. A. Characterization of the murine endothelial nitric oxide synthase promoter. Biochim. Biophys. Acta, 1998, 1443, 352-357.
51. Tai, S.C.; Robb, G.B.; Marsden, P.A. Endothelial Nitric Oxide Synthase: A new paradigm for gene regulation in the injured blood vessel. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 405-412.
52. Lai, P.F.H.; Mohamed, F.; Monge, J.C.; Stewart, D.J. Downregulation of eNOS mRNA expression by TNF[alpha]: identification and functional characterization of RNA-protein interactions in the 3'UTR. Cardiovasc. Res., 2003, 59, 160-168.
53. 2+-Calmodulin and caveolin. J. Biol. Chem., 1997, 272, 15583-15586.
54. Rotherbeg, K.G.; Heuser, J.E.; Donzell, W.C.; Ying, Y.S.; GLlenney, J.R.; Anderson, R.G.W. Caveolin, a protein component of caveolae membrane coats. Cell, 1992, 68, 673-682.
55. Ju, H.; Zou, R.; Venema, V.J.; Venema, R.C. direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J. Biol. Chem., 1997, 272, 18522-18525. (Pubitemid 27318186)
56. Garcia-Cadena, G.; Martasek, P.; Masters, B.S.S.; Skidd, P.M.; Couet, J.; Li, S.; Lsinati, M.P.; Sessa, W.C. dissecting the interaction between nitric oxide synthase (nos) and caveolin. functional significance of the nos caveolin binding domain in vivo. J. Biol. Chem., 1997, 272, 25437-25440.
57. Cirino, G.; Fiorucci, S.; Sessa, W.C. Endothelial nitric oxide synthase: the cinderella of inflammation? Trends Pharmacol. Sci., 2003, 24, 91-95.
58. Dudzinski, D.M.; Michel, T. Life history of eNOS: Partners and pathways. Cardiovas. Res., 2007, 75, 247-260.
59. Sessa, W.C. eNOS at a glance. J. Cell Sci., 2004, 117, 2427-2429.
60. Butt, E.; Bernhardt, M.; Smolesnski, A.; Kotsonis, P.; Frohlich, L.G.; Sickmann, A.; Meyer, H.E.; Lohman, S.M.; Schmidt, H.H. endothelial nitric-oxide synthase (type iii) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotidedependent protein kinases. J. Biol. Chem., 2000, 275, 5179-5187.
61. Fulton, D.; Fontana, J.; Sowa, G.; Gratton, J.P.; Lin, M.; Li, K.X.; Michell, B.; Kemp, B.E.; Rodman, D.; Sessa, W.C. localization of endothelial nitric-oxide synthase phosphorylated on serine 1179and nitric oxide in golgi and plasma membrane defines the existence of two pools of active enzyme. J. Biol. Chem., 2002, 277, 4277-4284.
62. Fulton, D.; Gratton, J.P.; McCabe, T.J.; Fontana, J.; Fujio, Y.; Walsh, K.; Franke, T.F.; Papapetropoulos, A.; Sessa, W.C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature, 1999, 399, 597-601.
63. Fontana, J.; Fulton, D.; Chen, Y.; Fairchild, T. A.; McCabe, T.J.; Fujita, N.; Tsuruo, T.; Sessa, W.C. Domain mapping studies reveal that the m domain of hsp90 serves as a molecular scaffold to regulate akt-dependent phosphorylation of endothelial nitric oxide synthase and no release. Circ. Res., 2002, 90, 866-873.
64. Takayashi, S.; Mendelsohn, M.E. Synergistic activation of endothelial nitric-oxide synthase (eNOS) by HSP90 and Akt: calciumindependent eNOS activation involves formation of an hsp90-aktcam- bound eNOS complex. J. Biol. Chem., 2003, 278, 30821-30827.
65. Erwin, P.A.; Lin, A.J.; Golan, D.E.; Michel, T. Receptor-regulated dynamic s-nitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells. J. Biol. Chem., 2005, 280, 19888-19894.
66. Erwin, P.A.; Mitechell, D.A.; Sartoretto, J.; Marletta, M.A.; Michel, T. Subcellular targeting and differential S-Nitrosylation of endothelial nitric-oxide synthase. J. Biol. Chem., 2006, 281, 151-157.
67. B.R. Crane, A.S. Arvai, D.K. Ghosh, C. Wu, E.D. Getzoff, D.J. Stuehr, J.A. Tainer. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science, 1998, 279, 2121-2126.
68. Fischmann, T.O.; Hruza, A.; Niu, X.D.; Fossetta, J.D.; Lunn, C.A.; Dolphin, E.; Prongay, A.J.; Reichert, P.; Lundell, D.J.; Narula, S.K.; Weber, P.C. Structural characterization of nitric oxide synthase isoforms reveals striking active site conservation. Nat. Struct. Biol., 1999, 6, 233-242.
69. Venema, V.J.; Ju, H.; Zou, R.; Venema, R.C. Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain. J. Biol. Chem., 1997, 272, 28187-28190.
70. Panda, K.; Adak, S.; Aulak, K.S.; Santolini, J.; McDonald, J.F.; Stuehr, D.J. Distinct influence of N-terminal elements on neuronal nitric-oxide synthase structure and catalysis. J. Biol. Chem., 2003, 278, 37122-37131.
71. Siddhanta, U.; Wu, C.; Abu-Soud, H.M.; Zhang, J.; Ghosh, D.K.; Stuehr, D.J. Heme iron reduction and catalysis by a nitric oxide synthase heterodimer containing one reductase and two oxygenase domains. J. Biol. Chem., 1996, 271, 7309-7312. (Pubitemid 26106995)
72. Jaffrey, S.R.; Snyder, S.H. PIN: an associated protein inhibitor of neuronal nitric oxide synthase. Science, 1996, 274, 774-777.
73. El-Mlili, N.; Rodrigo, R.; Naghizadeh, B.; Cauli, O.; Felipo, V. Chronic hyperammonemia reduces the activity of neuronal nitric oxide synthase in cerebellum by altering its localization and increasing its phosphorylation by calcium-calmodulin kinase II. J. Neurochem., 2008, 106, 1440-1449.
74. Rameau, G.A.; Chiu, L.Y.; Ziff, E.B. Bidirectional regulation of neuronal nitric oxide synthase phosphorylation at serine 847 by the n-methyl-d-aspartate receptor. J. Biol. Chem., 2004, 279, 14307-14314.
75. Rameau, G.A.; Tukey, D.S.; Garcin-Hosfield, E.D.; Titcombe, R.F.; Misra, C.; Khatri, L.; Getzoff, E.D.; Ziff, E.B. Biphasic coupling of neuronal nitric oxide synthase phosphorylation to the nmda receptor regulates ampa receptor trafficking and neuronal cell death. J. Neurosci., 2007, 27, 3445-3455.
76. Li, H.; Poulos, T.L. Structure-function studies on nitric oxide synthases, J. Inorg. Biochem., 2005, 99, 293-305.
77. Boissel, J.P.; Zelenka, M.; Godtel-Armbrust, U.; Feuerstein, T.J.; Forstermann U. Transcription of different exons 1 of the human neuronal nitric oxide synthase is dynamically regulated in a celland stimulus-specific manner. Biol. Chem., 2003, 384, 351-362.
78. Bros, M.; Boissel, J.P.; Godtel-Armbrust, U.; Forstermann U. Transcription of human neuronal nitric oxide synthase mRNAs derived from different first exons is partly controlled by exon 1-specific promoter sequences. Genomics, 2006, 87, 463-473.
79. Saur, D.; Seidler, B.; Paehge, H.; Schusdziarra, V.; Allescher H.D. (Complex regulation of human neuronal nitric-oxide synthase exon 1c gene transcription. Essential role of Sp and ZNF family members of transcription factors. J. Biol. Chem., 2002, 277, 25798-25814.
80. Chen, L.; Fischle, W.; Verdin, E.; Greene, W.C. Duration of nuclear NF-B action regulated by reversible acetylation. Science, 2001, 293, 1653-1657.
81. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet., 2009, 10, 32-42.
82. Li, Y.; Zhao, Y.; Li, G.; Wang, J.; Li, T.; Li, W.; Lu, J. Regulation of neuronal nitric oxide synthase exon 1f gene expression by nuclear factor-kappaB acetylation in human neuroblastoma cells. J. Neurochem., 2007, 101, 1194-1204.
83. Hingorani, A.D.; Liang, C.F.; Fatibene, J.; Lyon, A.; Monteith, S.; Parsons, A.; Haydock, S.; Hopper, R.V.; Stephens, N.G.; O'Shaughnessy, K.M.; Brown, M.J. A common variant of the endothelial nitric oxide synthase (Glu298--Asp) is a major risk factor for coronary artery disease in the UK. Circulation, 1999, 100, 1515-1520.
84. Lembo, G.; De Luca, N.; Battagli, C.; Iovino, G.; Aretini, A.; Musicco, M.; Frati, G.; Pompeo, F.; Vecchione, C.; Trimarco, B. A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke, 2001, 32, 735-740.
85. Testa, A.; Spoto, B.; Tripepi, G.; Mallamaci, F.; Malatino, L.; Fatuzzo, P.; Maas, R.; Boeger, R.; Zoccali, C. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. J. Hypertens., 2005, 23, 1825-1830.
86. Bayazit, Y.A.; Yilmaz, M.; Erda,l E.; Ciftci, T.U.; Ceylan, A.; Kokturk, O.; Celenk, F.; Kemaloglu, Y.K. Role of nitric oxide synthase gene intron 4 and exon 7 polymorphisms in obstructive sleep apnea syndrome. Eur. Arch. Otorhinolaryngol., 2009, 266, 449-454.
87. Holla, L.I.; Jurajda, M.; Pohunek, P.; Znojil, V. Haplotype analysis of the endothelial nitric oxide synthase gene in asthma. Hum. Immunol., 2008, 69, 306-313.
88. Vazgiourakis, V.; Sidiropoulos, P.; Bertsias, G.; Koutsounaki, E.; Fragouli, E.; Raptopoulou, A.; Kritikos, H.; Boumpas, D.T.; Goulielmos, G.N. Association of the nitric oxide synthase (eNOS) gene polymorphism with increased risk for both lupus glomerulonephritis and rheumatoid arthritis in a single genetically homogeneous population. Lupus, 2007, 16, 867-874.
89. Alasehirli, B.; Balat, A.; Barlas, O.; Kont, A. Nitric oxide synthase gene polymorphisms in children with minimal change nephritic syndrome. Pediatr. Int., 2009, 51, 75-78.
90. Reif, A.; Herterich, S.; Strobel, A.; Ehlis, A.C.; Saur, D.; Jacob, C.P.; Wienker, T.; Töpner, T.; Fritzen, S.; , Walter, U.; Schmitt, A.; Fallgatter, A.J.; Lesch, K.P. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex functions. Mol. Psychiatry, 2006, 11, 286-300.
91. Levecque, C.; Elbaz, A.; Clavel, J.; Richard, F.; Vidal, J.S.; Amouyel, P.; Tzourio, C.; Alpérovitch, A.; Chartier-Harlin, M.C. Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. Hum. Mol. Genet., 2003, 12, 79-86.
92. Martín, M.C.; Martinez, A.; Mendoza, J.L.; Taxonera, C.; Díaz- Rubio, M.; Fernández-Arquero, M.; de la Concha, E.G.; Urcelay, E. Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility. Immunogenetics, 2007, 59, 833-837.
93. Sawa, T.; Mounawar, M.; Tatemichi, M.; Gilibert, I.; Katoh, T.; Ohshima, H. Increased risk of gastric cancer in Japanese subjects is associated with microsatellite polymorphisms in the heme oxygenase- 1 and the inducible nitric oxide synthase gene promoters. Cancer Lett., 2008, 269, 78-84.
94. Batra, J.; Pratap Singh, T.; Mabalirajan, U.; Sinha, A.; Prasad, R.; Ghosh, B. Association of inducible nitric oxide synthase with asthma severity, total serum immunoglobulin E and blood eosinophil levels. Thorax, 2007, 62, 16-22.
95. Basta, G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis, 2008, 196, 9-21.
96. Schmidt, A.M.; Vianna, M.; Gerlach, M.; Brett, J.; Ryan, J.; Kao, J.; Esposito, C.; Hegarty, H.; Hurley, W.; Clauss, M. Isolation ndcharacterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem., 1992, 267, 14987-14997.
97. Yan, S.F.; Ramasamy, R.; Schmidt, A.M. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat. Clin. Pract. Endocrinol. Metab., 2008, 4, 285-293.
98. Rojas, A.; Mercadal, E.; Figueroa, H.; Morales, M.A. Advanced glycation and ROS: a link between diabetes and heart failure. Curr. Vasc. Pharmacol., 2008, 6, 44-51.
99. Schmidt, A.M.; Stern, D.M. Receptor for AGE (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. Front. Biosci., 2001, 6, D1151-1160.
100. Sugaya, K.; Fukagawa, T.; Matsumoto, K.; Mita, K.; Takahashi, E.; Inoko, H.; Ikemura, T. Genomics, 1994, 23, 408-419.
101. Schmidt, A.M.; Yan, S.D.; Yan, S.F.; Stern, D. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses J. Clin. Invest., 2001, 108, 949-955.
102. Neeper, M.; Schmidt, A.M.; Brett, J.; Yan, S.D.; Wang, F.; Pan, Y.C.; Elliston, K.; Stern, D.; Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins, J. Biol. Chem., 1992, 267, 14998-15004.
103. Xie, J.; Reverdatto, S.; Frolov, A.; Hoffmann, R.; Burz, D.S.; Shekhtman, A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE), J. Biol. Chem., 2008, 283, 27255-27269.
104. Brett, J.; Schmidt, A.M.; Yan, S.D.; Zou, Y.S.; Weidman, E.; Pinsky, D.; Nowygrod, R.; Neeper, M.; Przysiecki, C.; Shaw, A. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol., 1993, 143, 1699-1712.
105. Srikrishna, G.; Huttunen, H.J.; Johansson, L.; Weigle, B.; Yamaguchi, Y.; Rauvala, H.; Freeze, H.H. N -Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth, J. Neurochem., 2002, 80, 998-1008.
106. Hudson, B.I.; Carter, A.M.; Harja, E.; Kalea, A.Z.; Arriero, M.; Yang, H.; Grant, P.J.; Schmidt, A.M. Identification, classification, and expression of RAGE gene splice variants. FASEB J., 2008, 22, 1572-1580.
107. Geroldi, D.; Colomba, F.; Emanuele, E. Soluble receptor for advanced glycation end products: From disease marker to potential therapeutic target. Curr. Med. Chem., 2006, 13, 1971-1978.
108. Kislinger, T.; Fu, C.; Huber, B.; Qu, W.; Taguchi, A.; Du, S.; Hofmann, M.; Yan, S.F.; Pischetsrieder, M.; Stern, D.; Schmidt, AM. N(epsilon)- (carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem., 1999, 274, 31740-31749.
109. Cho, S.J.; Roman, G.; Yeboah, F.; Konishi, Y. The road to advanced glycation end products: A mechanistic perspective. Curr. Med. Chem., 2007, 14, 1653-1671.
110. Sell, D.; Monnier, V. Structure elucidation of a senescence crosslink from human extracellular matrix: implications of pentoses in the aging process. J. Biol. Chem., 1989, 264, 21597-21602.
111. van Heijst, J.W.; Niessen, H.W.; Hoekman, K.; Schalkwijk, C.G. Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine. Ann. NY Acad. Sci., 2005, 1043, 725-733.
112. Ledl, F.; Schleicher, E. New aspects of the Maillard reaction in foods and in the human body. Angew. Chem. Int. Ed., 1989, 29, 565-594.
113. Gasser, A.; Forbes, J. Advanced glycation: implications in tissue damage and disease. Protein Pept. Lett., 2008, 15, 385-391.
114. Uribarri, J.; Cai, W.; Sandu, O.; Peppa, M.; Goldberg, T.; Vlassara, H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann. NY Acad. Sci., 2005, 1043, 461-466.
115. Chuyen, N. Toxicity of the AGEs generated from the Maillard reaction: on the relationship of food-AGEs and biological-AGEs. Mol. Nutr. Food Res., 2006, 50, 1140-1149.
116. Yan, S.D.; Chen, X.; Fu, J.; Chen, M.; Zhu, H.; Roher, A.; Slattery, T.; Zhao, L.; Nagashima, M.; Morser, J.; Migheli, A.; Nawroth, P.; Stern, D, Schmidt, A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature, 1996, 382, 685-691.
117. Yan, S.D.; Zhu, H.; Zhu, A.; Golabek, A.; Du, H.; Roher, A.; Yu, J.; Soto, C.; Schmidt, A.M.; Stern, D.; Kindy, M. Receptor dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med., 2000, 6, 643-651.
118. Marenholz, I.; Heizmann, C.W.; Fritz, G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem. Biophys. Res. Commun., 2004, 322, 1111-1122.
119. Heizmann, C.W.; Ackermann, G.E.; Galichet, A. Pathologies involving the S100 proteins and RAGE. Subcell. Biochem., 2007, 45, 93-138.
120. Lotze, M.T. Tracey, K.J. High mobility group box-1 protein (HMGB1): nuclear weapon indamage-associated molecular pattern the immune arsenal. Nat. Rev. Immunol., 2005, 5, 331-342.
121. Coffelt, S.B.; Scandurro, AL. Tumors sound the alarmin(s). Cancer Res., 2008, 68, 6482-6485.
122. Bucala, R.; Tracey, K.J.; Cerami, A. Advanced glycosylation roducts quench nitric oxide and mediate defective endotheliumdependent vasodilatation in experimental diabetes. J. Clin. Invest., 1991, 87, 432-438.
123. Verbeke, P.; Perichon, M.; Friguet, B.; Bakala, H. Inhibition of nitric oxide synthase activity by early and advanced glycation end products in cultured rabbit proximal tubular epithelial cells. Biochim. Biophys. Acta., 2000, 1502, 481-494.
124. Uhlmann, S.; Rezzoug, K.; Friedrichs, U.; Hoffmann, S.; Wiedemann, P. Advanced glycation end products quench nitric oxide in vitro. Arch. Clin. Exp. Ophthalmol., 2002, 240, 860-866.
125. Lauer, T.; Rassaf, T.; Planitz, C.; Preuss, R.; Krause, R.; Henle, T.; Deussen, A. Evidence against nitric oxide-quenching effects of chemically defined Maillard reaction products. Horm. Metab. Res., 2008, 40, 233-238.
126. Rojas, A.; Caveda, L.; Romay, C.; López, E.; Valdés, S.; Padrón, J.; Glaría, L.; Martínez, O.; Delgado, R. Effect of advanced glycosylation end products on the induction of nitric oxide synthase in murine macrophages. Biochem. Biophys. Res. Commun.,1996, 225, 358-362.
127. Sugimoto, H.; Shikata, K.; Wada, J.; Horiuchi, S.; Makino, H. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factoralpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia, 1999, 42, 878-886.
128. Seftel, A.D.; Vaziri, N.D.; Ni, Z.; Razmjouei, K.; Fogarty, J.; Hampel, N.; Polak, J.; Wang, R.Z.; Ferguson, K.; Block, C.; Haas, C. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology, 1997, 50, 1016-1026.
129. Lin, C.H.; Lin, Y.F.; Chang, M.C.; Wu C.H.; Ho Y.S.; Lee H.M. Advanced glycosylation end products induce nitric oxide synthase expression in C6 glioma cells: involvement of a p38 MAP kinasedependent mechanism. Life Sci., 2001, 69, 2503-2515.
130. Wu, C.H.; Huang, C.M.; Lin, C.H, Ho, Y.S.;, Chen C.M.; Lee, H.M. Advanced glycosylation end-products induce NF-kappaB dependent iNOS expression in RAW 264.7 cells. Mol. Cell Endocrinol., 2002, 194, 9-17.
131. Chang, P.C.; Chen, T.H.; Chang, C.J.; Hou, C.C.; Chan, P.; Lee, H.M. Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney Int., 2004, 65, 1664-1675
132. Nah, S.S.; Choi, I.Y.; Lee, C.K.; Oh, J.S.; Kim, Y.G.;, Moon, H.B.; Yoo, B. Effects of advanced glycation end products on the expression of COX-2, PGE2 and NO in human osteoarthritic chondrocytes. Rheumatology, 2008, 47, 425-431.
133. Sumi, D.; Ignarro, L.J. Regulation of inducible nitric oxide synthase expression in advanced glycation end product-stimulated raw 264.7 cells: the role of heme oxygenase-1 and endogenous nitric oxide. Diabetes, 2004, 53, 1841-1850.
134. Amore, A.; Cirina, P.; Mitola, S.; Peruzzi, L.; Gianoglio, B.; Rabbone, I.; Sacchetti, C.; Cerutti, F.; Grillo, C.; Coppo, R. Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells. Kidney Int., 1997, 51, 27-35.
135. Chakravarthy, U.; Hayes, R.G.; Stitt, A.W.; McAuley, E.; Archer, D.B. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes, 1998, 47, 945-952.
136. Yoshizumi, M.; Perrella, M.A.; Burnett, J.C.; Lee, M. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ. Res., 1993, 73, 205-209.
137. Lu, J.L.; Schmiege, L.M.; Kuo, L.; Liao, J. Downregulation of endothelial constitutive nitric oxide synthase expression by lipopolysaccharide. Biochem. Biophys. Res. Commun., 1996, 225, 1-5.
138. Rojas, A.; Romay, S.; González, D.; Herrera, B.; Delgado, R.; Otero, K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ. Res., 2000, 86, 50-54.
139. Searles, C.D.; Harrison, D.G.; Ramasamy, S. Post-transcriptional regulation of endothelial nitric oxide synthase gene expression during cell growth. Circulation, 1996, 94, I-154. Abstract.
140. Rashid, G.; Benchetrit, S.; Fishman, D.; Bernheim, J. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int., 2004, 66, 1096-1099.
141. Xu, B.; Chibber, R.; Ruggiero, D.;, Kohner, E.; Ritter, J.; Ferro, A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J., 2003, 17, 1289-1291.
142. Xu, B.; Ji, Y.; Yao, K.; Cao, Y.X.; Ferro, A. Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation endproducts but not glucose: relevance to diabetes. Clin. Sci. (Lond.), 2005, 109, 439-446.
143. Brouwers, O.; Teerlink, T.; van Bezu, J.; Barto, R.; Stehouwer, C.D.; Schalkwijk, C.G. Methylglyoxal and methylglyoxal-arginine adducts do not directly inhibit endothelial nitric oxide synthase. Ann. NY Acad. Sci., 2008, 1126, 231-234.
144. Usta, M.F.; Kendirci, M.; Gur, S.; Foxwell, N.A.; Bivalacqua, T.J.; Cellek, S.; Hellstrom, W.J. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin- induced diabetic rats: preventive vs. curative treatment. J. Sex Med., 2006, 3, 242-250.
145. Korenaga, K.; Micci, M.A.; Taglialatela, G.; Pasricha, P.J. Suppression of nNOS expression in rat enteric neurones by the receptor for advanced glycation end-products. Neurogastroenterol. Motil., 2006, 18, 392-400.
146. Jeyabal, P.V.; Kumar, R.; Gangula, P.R.; Micci, M.A.; Pasricha, P. J.Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats. Neurogastroenterol. Motil., 2008, 20, 253-261.
147. Esposito, G.; De Filippis, D.; Cirillo, C.; Sarnelli, G.; Cuomo, R.; Iuvone ,T. The astroglial-derived S100beta protein stimulates the expression of nitric oxide synthase in rodent macrophages through p38 MAP kinase activation. Life Sci., 2006, 78, 2707-2715.
148. Hu, J.; Castets, F.; Guevara, J.L.; Van Eldik, L.J. S100 beta stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes. J. Biol. Chem., 1996, 271, 2543-2547.
149. Ren, D.; Sun, R.; Wang, S. Role of inducible nitric oxide synthase
150. Jang, J.H.; Surh, Y.J. AP-1 mediates beta-amyloid-induced iNOS expression in PC12 cells via the ERK2 and p38 MAPK signaling pathways. Biochem. Biophys. Res. Commun., 2005, 331, 1421-1428.
151. Weldon, D.T.; Rogers, S.D.; Ghilardi, J.R.; Finke, M.P.; Cleary, J.P.; O′Hare, E.; Esler, W.P.; Maggio, J.E.; Mantyh, P.W. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J. Neurosci., 1998, 18, 2161-2173.
152. Stepanichev, M.Y.; Onufriev, M.V.; Yakovlev, A.A.; Khrenov, A.I.; Peregud, D.I.; Vorontsova, O.N.; Lazareva, N.A.; Gulyaeva, NV. Amyloid-beta (25-35) increases activity of neuronal NOsynthase in rat brain. Neurochem. Int., 2008, 52, 1114-1124.
153. Gentile, M.T.; Vecchione, C.; Maffei, A.; Aretini, A.; Marino, G.; Poulet, R.; Capobianco, L.; Selvetella, G.; Lembo, G. Mechanisms of soluble beta-amyloid impairment of endothelial function. J. Biol. Chem., 2004, 279, 48135-48142.
154. Sutton, E.T.; Hellermann, G.R.; Thomas, T. beta-amyloid-induced endothelial necrosis and inhibition of nitric oxide production. Exp. Cell Res., 1997, 230, 368-376. (Pubitemid 27190657)
155. Suhara, T.; Magrané, J.; Rosen, K.; Christensen, R.; Kim HS, Zheng, B.; McPhie, D.L.; Walsh, K.; Querfurth, H. Abeta42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signaling-dependent mechanism. Neurobiol. Aging., 2003, 24, 437-451.
156. Bros, M.; Boissel, J.P.; Gödtel-Armbrust, U.; Förstermann, U. The untranslated region of exon 2 of the human neuronal nitric oxide synthase (NOS1) gene exerts regulatory activity. Gene, 2007, 405, 36-46.
157. Huige, L.; Wallerath, T.; Förstermann, U. Physiological mechanisms regulating the expression of endothelial-type NO synthase. Nitric Oxide, 2002, 7, 132-147. (Pubitemid 35177005)